In summary, while the cGAS-STING signaling pathway demonstrates immense potential in HNSCC therapy, further research and clinical practice are required to ascertain its efficacy and safety in both HPV-positive and HPV-negative patients. The gene discussed is CGAS; the disease is head and neck squamous cell carcinoma.